BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: EP leads to continue as PMAs, but docs dislike innovation lag

July 9, 2012
By Mark McCarty

Washington roundup: FDA's final CADe guidance explicitly mentions OUS data

July 6, 2012
By Mark McCarty

Washington roundup: FDA inks UDI rule proposal; new surveillance tool en route

July 5, 2012
By Mark McCarty

Washington roundup: FDA posts warning letter to Cook one year after issuance

July 3, 2012
By Mark McCarty

FDA advisory committee: Panel suggests MRI to check on symptomatic MoM patients

July 2, 2012
By Mark McCarty

Washington roundup: Roberts casts deciding vote to uphold Affordable Care Act

June 29, 2012
By Mark McCarty
Chief Justice John Roberts surprised almost the entire nation in voting to uphold the Affordable Care Act after months of speculation that Justice Anthony Kennedy would provide the deciding vote, and the Affordable Care Act is nearly intact going forward. The decision reinforces the most sweeping piece of healthcare legislation since the inception of Medicare in 1965, and sets up a controversial vote in the House of Representatives on legislation to repeal the ACA.
Read More

Counting to 51: The fate of the device tax and the Affordable Care Act

June 28, 2012
By Mark McCarty
The biggest judicial showdown in quite a while is finally over, and here are a couple of things to consider while we’re playing numerology games in an effort to interpret the scribblings of nine citizens in black robes we all now refer to as SCOTUS. I for one can understand why the Supreme Court was unimpressed with the attempt to argue the validity of the Affordable Care Act on the basis of the Commerce Clause. In this decision the Court basically said the government cannot force citizens to participate in commerce, a position that comports with precedent. By the way,...
Read More

FDA advisory committee: Day one of MoM hearing offers more questions than answers

June 28, 2012
By Mark McCarty

Washington roundup: Senate passes S. 3187 via a 92-4 vote. Oval Office next

June 27, 2012
By Mark McCarty
The Senate passed the FDA user fee bill for fiscal years 2013-2017 by a majority of 92-4, sending the bill on to the White House where President Obama is expected to quickly apply his signature. The voting process did not come off without a hitch, however, as one member of the Senate put up a fight over the absence of provisions for track-and-trace of pharmaceuticals. Sen. Bernie Sanders (I-Vermont), a bitter critic of the pharmaceutical industry, provided one of only four nay votes, joined by Sen. Tom Coburn (R-Oklahoma), one of the authors of a late-stage track-and-trace amendment.
Read More

Washington roundup: Durata failure due to external abrasion, but some not sold

June 26, 2012
By Mark McCarty
Previous 1 2 … 424 425 426 427 428 429 430 431 432 … 575 576 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Rubber duck dressed up as a doctor

    In 2025, science’s biggest story was political

    BioWorld
    In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
  • Abstract blue human heart with red cardio pulse line and red circle

    FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

    BioWorld
    Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
  • Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

    BioWorld Science
    Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing